Cancer accounted for nearly 10 million deaths in 2020 – almost one in every six deaths globally – according to the World Health Organization.

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Researchers propose a novel system that uses standing surface acoustic waves to separate circulating tumor cells from red blood cells with unprecedented precision and efficiency. The platform ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

DARPA wants to know if modifying red blood cells can help warfighters "operate more effectively in dangerous or extreme ...

Some of those patients will experience refractory cancer – cancer that does not respond to initial treatment or becomes ...

RBC Capital analyst Shelby Tucker maintained a Buy rating on PG&E (PCG – Research Report) on January 13 and set a price target of $24.00.

On Wednesday, RBC Capital Markets analyst Andrew Brooke upgraded DCC Plc. (DCC:LN) (OTC: DCCPF) stock rating from Sector Perform to Outperform and raised the price target to £60.00 from £58.00. Brooke ...

On January 3rd, RBC Capital upped their price target of the stock to $420 from $365 and reiterated an “Outperform” rating of the stock. The firm anticipates that 2025 will be another promising ...

On Tuesday, RBC Capital Markets adjusted its price target for Sherwin-Williams (NYSE:SHW) stock, listed on the New York Stock Exchange under the ticker NYSE:SHW, reducing it to $438 from the previous ...